Atopic Dermatitis Study Notes

Course Overview and Derm Study Strategies

  • Study Tips for Dermatology:

    • Know the basic presentation of each condition, including key patient characteristics, physical location on the body, and signs or symptoms.

    • Memorize brand and generic names and their specific indications.

    • Utilize the "Derm Exam Resource" worksheet for Brand/Generic names.

    • Prioritize studying treatment algorithms, specifically identifying first-line, second-line, and alternative therapeutic options.

    • Do not neglect non-pharmacologic treatment options.

    • Exam focus: Choosing the most appropriate therapy for a given scenario.

Topical Corticosteroid (TCS) Potency Classification

  • Low Potency (Class 6 & 7):

    • Mnemonic: "HAFD the strength"

    • Hydrocortisone, Alclometasone, Fluocinolone, Desonide

    • Hydrocortisone (0.5%0.5\% & 1.0%1.0\%): OTC Brand names: CortaidCortaid , CortizoneCortizone,LanacortLanacort. Route: Topical. Dosing: Apply BID (Twice daily).

    • Hydrocortisone (2.5%2.5\%): Brand name: HytoneHytone . Status: Rx.

    • Alclometasone: Brand name: AclovateAclovate. Status: Rx.

    • Fluocinolone acetonide: Brand name: SynalarSynalar. Status: Rx.

    • Desonide: Brand name: DesOwenDesOwen. Status: Rx.

  • Medium Potency (Class 3 - 5):

    • Mnemonic: "For Her Majesty VAL, a MEDIUM rare T-Bone steak."

    • Fluticasone propionate: Brand name: CutivateCutivate. Route: Topical. Dosing: Apply BID. Status: Rx.

    • Hydrocortisone valerate: Brand name: WestcortWestcort. Status: Rx.

    • Mometasone furoate: Brand name: EloconElocon. Status: Rx.

    • Betamethasone valerate: Brand name: ValisoneValisone. Status: Rx. (Note: Potency may vary depending on concentration/strength).

    • Triamcinolone acetonide: Brand name: KenalogKenalog. Status: Rx. (Note: Potency may vary depending on concentration/strength).

  • High Potency (Class 2):

    • Mnemonic: "The -CINONIDEs and DI- rhyme with HIGH."

    • Amcinonide: Brand name: CyclocortCyclocort. Route: Topical. Dosing: Apply BID. Status: Rx.

    • Fluocinonide: Brand name: LidexLidex. Status: Rx.

    • Halocinonide: Brand name: HalogHalog. Status: Rx.

    • Diflorasone diacetate: Brand name: PsorconPsorcon. Status: Rx.

  • Very High Potency / Super-potent (Class 1):

    • Mnemonic: "My BETA fish, NATE is VERY HIGH-ly aggressive."

    • Betamethasone dipropionate: Brand name: DiproleneDiprolene. Route: Topical. Dosing: Apply BID. Status: Rx.

    • Halobetasol propionate: Brand names: TemovateTemovate, UltravateUltravate. Status: Rx.

Non-Steroidal Therapeutic Agents

  • Topical Calcineurin Inhibitors (TCI):

    • Tacrolimus ointment: Brand name: ProtopicProtopic. Route: Topical. Dosing: Apply BID for flares; BIW (Twice weekly) for maintenance. Status: Rx.

    • Pimecrolimus cream: Brand name: ElidelElidel. Route: Topical. Dosing: Apply BID. Status: Rx.

  • Janus Kinase (JAK) Inhibitors:

    • Ruxolitinib cream: Brand name: OpzeluraOpzelura. Route: Topical. Status: Rx.

    • Delgocitinib cream: Brand name: AnzupgoAnzupgo. Route: Topical. Indicated for moderate to severe AD on hands/wrists only.

    • Abrocitinib: Brand name: CibinqoCibinqo. Route: Oral. Status: Rx.

    • Upadacitinib ER: Brand name: RinvoqRinvoq. Route: Oral. Status: Rx.

  • Phosphodiesterase-4 (PDE-4) Inhibitors:

    • Crisaborole ointment (2%2\%): Brand name: EucrisaEucrisa. Route: Topical. Dosing: Apply BID. Status: Rx.

    • Roflumilast cream (0.15%0.15\% & 0.05%0.05\%): Brand name: ZoryveZoryve. Route: Topical. Dosing: Apply once daily. Status: Rx.

    • Difamilast ointment (1%1\%): Brand name: AdqueyAdquey. Route: Topical. Dosing: Apply BID.

  • Biologics / Monoclonal Antibodies:

    • Dupilumab: Brand name: DupixentDupixent. MOA: Inhibits IL4IL-4 and IL13IL-13. Route: SC (Subcutaneous). Dosing: Every 22 weeks.

    • Tralokinumab: Brand name: AdbryAdbry. MOA: Inhibits IL13IL-13. Route: SC. Dosing: Every 22 weeks.

    • Lebrikizumab: Brand name: EbglyssEbglyss. MOA: Inhibits IL13IL-13. Route: SC. Dosing: Every 22 weeks.

    • Nemolizumab: Brand name: NemluvioNemluvio. MOA: Inhibits IL31IL-31. Route: SC. Dosing: Every 44 weeks.

  • Topical Antibiotics:

    • Mupirocin ointment: Brand name: BactrobanBactroban. Route: Topical. Dosing: Apply BID-TID.

OTC Baths, Cleansers, and Moisturizers

  • Cleansers:

    • Mild, non-soap cleanser (CetaphilCetaphil): Used in place of soap.

    • Glycerin Soap (NeutrogenaNeutrogena): Contains TEA-Stearate and triethanolamine.

  • Colloidal Oatmeal:

    • Colloidal oatmeal (±\pm mineral oil): Brand name: AveenoOatmealBathAveeno Oatmeal Bath.

    • Administration: Use in warm bath; soak for 152015-20 minutes once or twice daily. Pat skin dry to leave a film of oatmeal.

  • Moisturizers and Emollients:

    • Petrolatum: Brand name: AquaphorAquaphor. Dosing: Apply 33 to 44 times daily (more if washing frequently).

    • Lanolin: Used as a moisturizer/emollient.

    • Urea: Mild keratolytic and humectant. Dosing: Apply 33 to 44 times daily.

    • Alpha hydroxy acid: Brand names: AmLactinAmLactin , LacHydrinLac-Hydrin. Generic: Ammonium lactate/Lactic acid.

Antihistamines

  • Topical Antihistamines:

    • Brand name: BenadrylBenadryl Cream/Gel. Generic: Diphenhydramine. Dosing: Apply BID. Maximum duration: 77 days due to sensitizing potential.

  • Oral Antihistamines (First Generation):

    • Diphenhydramine (BenadrylBenadryl): OTC. Dosage: 2550mg25-50\,mg PO QHS (at bedtime).

    • Hydroxyzine pamoate (VistarilVistaril): Rx. Dosage: PO TID-QID PRN (typically QHS due to sedation).

    • Hydroxyzine hydrochloride (AtaraxAtarax): Rx.

Clinical Definitions of Dermatitis

  • Dermatitis: A nonspecific term covering various disorders characterized by erythema (redness) and inflammation.

  • Xerosis: The medical term for dry skin.

  • Eczema: A group of inflammatory skin disorders, often of unknown cause.

  • Atopic Dermatitis (AD): A form of eczema ("atopic eczema") that is chronic, characterized by a lifetime of flares and remissions.

Presentation and Differentiating Characteristics

  • Atopic Dermatitis (AD):

    • Hallmark symptom: Pruritus (itching). "The itch that rashes."

    • Onset: Often in early childhood. 50%50\% diagnosed in 1st year of life (typically 232-3 months); 85%85\% by age 55.

    • Atopic Triad: Co-occurrence of Asthma, Allergic Rhinitis, and Atopic Dermatitis.

    • Location by Age:

      • Adults: Skin creases (flexure surfaces like antecubital and popliteal fossae), neck, and hands.

      • Children/Infants: Face (cheeks, forehead, neck) and extremities.

    • Forms of AD:

      • Acute: Intense pruritus, red papules/vesicles, clear exudate, crusts.

      • Subacute: Red, excoriated papules; scratching leads to scaly plaques.

      • Chronic: Lichenified (thickened) plaques.

  • Xerosis:

    • Common in older patients. Presents as rough skin, scales, and fissures. Pruritus and loss of flexibility occur. Usually found on limbs.

  • Contact Dermatitis:

    • Can affect anyone. Presents as papules or vesicles over inflamed skin. Irritant contact dermatitis often causes scaling and fissures. Itching/burning occurs specifically at the site of contact.

  • Dermatological Terminology:

    • Papule: A solid elevation up to 0.5cm0.5\,cm.

    • Excoriation: Skin abrasions typically from scratching.

    • Lichenification: Thickening of the skin with exaggerated markings.

    • Vesicle: Small, fluid-filled blister.

Severity Assessment and Digital Tools

  • SCORAD (Severity Scoring of Atopic Dermatitis) Index:

    • Calculation: SCORAD=A5+7B2+C\text{SCORAD} = \frac{A}{5} + \frac{7B}{2} + C

    • A (Extent): Percentage of area involved.

      • Head involvement is 4.5%4.5\% for adults (8.5%8.5\% for children under 22).

      • Trunk is 18%18\% (front) and 18%18\% (back).

      • Arms are 4.5%4.5\% each.

      • Legs are 9%9\% each.

    • B (Intensity): Rated 030-3 (Absence, Mild, Moderate, Severe) for Erythema, Edema/papulation, Oozing/Crusting, Excoriations, Lichenification, and Dryness (evaluated on uninvolved skin).

    • C (Subjective Symptoms): Visual analog scale (0100-10) for Pruritus and Sleep Loss (average of last 33 days/nights).

Triggers and Exclusions for Self-Care

  • Common Triggers:

    • Food: Eggs, milk, peanuts, soy, wheat, nuts, strawberries.

    • Aeroallergens: Dust mites, cat dander, mold, pollen.

    • Airborne Irritants: Tobacco smoke, air pollution.

    • Others: Cosmetics/fragrances, psychological stress, extreme temperatures, excessive hand washing, irritating clothing (wool/synthetics), dyes/preservatives.

Treatment Algorithms and Non-Pharmacologic Care

  • General Algorithm:

    • Baseline: Basic therapy involving moisturizers and non-pharmacologic interventions.

    • Mild-Moderate: Topical steroids, TCIs, PDE-4 inhibitors, or topical JAK inhibitors.

    • Severe: Systemic immunosuppression.

  • Bathing Recommendations:

    • Brief sessions (353-5 minutes).

      • Frequency: 232-3 times per week (sponge baths on other days).

      • Water temperature: Lukewarm/tepid (not more than 33^{\circ} above body temperature).

      • Cleansers: Non-soap (CetaphilCetaphil, NeutrogenaNeutrogena glycerin soap).

      • Moisturizing: Apply scent-free moisturizer liberally immediately after bathing while skin is still damp.

Pharmacotherapy: Detailed Agent Profiles

  • Emollients and Moisturizers:

    • Types: Lotions (thinnest), Creams, Ointments (thickest/most lipophilic).

    • MOA: Fill space between desquamating skin scales.

    • Ointments: Occlusive, provide better hydration and increased drug absorption. Avoid on weeping/infected skin.

    • Side Effects: Often caused by fragrances or ingredients like lanolin.

  • Urea:

    • MOA: Keratolytic; increases water uptake in stratum corneum; binds skin proteins to increase elasticity.

    • Strengths: 10%10\% for simple dry skin; 2030%20-30\% for resistant scales.

    • Side Effects: Stinging or burning on broken skin.

  • TCS Adverse Drug Reactions (ADRs):

    • Cutaneous: Atrophy (skin thinning), telangiectases (visible small blood vessels), striae (stretch marks), acne, hypopigmentation, alopecia, or hypertrichosis.

    • Systemic Risk Factors: Long duration, high potency, use on large BSA, application to thin skin (face, genitals, intertriginous areas), or application to broken skin.

    • Specific Systemic ADRs: Adrenal suppression, Cushing’s syndrome, decreased growth in children, osteoporosis, glaucoma, increased infection risk, hypertension, centripetal fat distribution, and hypokalemia.

  • Topical Calcineurin Inhibitors (TCIs):

    • Advantages: No skin atrophy; can be used on sensitive areas for prolonged (episodic) periods.

    • Side Effects: Transient stinging/burning.

    • Black Box Warning (BBW): Rare malignancies (skin cancer, lymphoma). Avoid in immunocompromised patients (HIV, chemotherapy). Sunscreen must be used.

  • Topical Janus Kinase (JAK) Inhibitors:

    • BBW: Serious infections, mortality, malignancy (lymphoma, lung cancer), MACE (Major Adverse Cardiovascular Events like heart attack/stroke), and thrombosis (DVT, PE, arterial thrombosis).

Dosing and the Fingertip Method

  • The Fingertip Unit (FTU):

    • 1 fingertip (from tip of finger to first joint)=0.5g1 \text{ fingertip (from tip of finger to first joint)} = 0.5\,g.

    • 1 fingertip1 \text{ fingertip} covers the area of 2 adult hands2 \text{ adult hands}.

    • 1 hand-print1% BSA1 \text{ hand-print} \approx 1\% \text{ BSA}.

    • Therefore: 0.5g=2% BSA0.5\,g = 2\% \text{ BSA}; 1g=4% BSA1\,g = 4\% \text{ BSA}.

  • Sample Calculation (Slide 79):

    • Scenario: Area is 22 hand-prints behind each knee (44 hand-prints total).

    • 4 hand-prints=2 FTUs=1.0g4 \text{ hand-prints} = 2 \text{ FTUs} = 1.0\,g per application.

    • Dosing: BID (2.0g2.0\,g per day).

    • Supply: 60g60\,g tube.

    • Duration: 60g2.0g/day=30 days\frac{60\,g}{2.0\,g/day} = 30 \text{ days}.

  • Sample Calculation (Slide 81):

    • Scenario: Area is 11 hand-print behind each knee (22 hand-prints total).

    • 2 hand-prints=1 FTU=0.5g2 \text{ hand-prints} = 1 \text{ FTU} = 0.5\,g per application.

    • Dosing: BID (1.0g1.0\,g per day).

    • Supply: 15g15\,g tube.

    • Duration: 15g1.0g/day=15 days\frac{15\,g}{1.0\,g/day} = 15 \text{ days}.

Questions & Discussion

  • Question: Which of the following is a LOW potency topical corticosteroid?

    • Answer: Hydrocortisone (DD).

  • Question: Which of the following is a VERY HIGH potency topical corticosteroid?

    • Answer: Clobetasol (BB).

  • Question: Which of the following is a JAK inhibitor?

    • Answer: Abrocitinib (AA).

  • Question: What is the hallmark symptom of atopic dermatitis?

    • Answer: Pruritus (CC).

  • Question: Which are included in the atopic triad?

    • Answer: Asthma, AT, and Allergic Rhinitis (I, II, and III).

  • Question: Which antihistamine is most likely to work for pruritus?

    • Answer: Diphenhydramine (AA) - primarily due to its sedative properties rather than H1 blockade efficacy in AD skin.

  • Question: Which is a prescription antihistamine?

    • Answer: Atarax (AA).

  • Question: Which does NOT have a BBW?

    • Answer: Desonide (BB). (Abrocitinib, Pimecrolimus, Tacrolimus, and Upadacitinib all have BBWs).